New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
07:55 EDTATRS, ATRS, BDX, BDX, ANTH, ANTH, NKTR, NKTR, SSH, SSH, IDRA, IDRA, LXRX, LXRX, ARAY, ARAY, ABBV, ABBV, INFI, INFI, JAZZ, JAZZ, IMMU, IMMUCowen to host a conference
34th Annual Global Healthcare Conference is being held in Boston on March 3-5 with webcasted company presentations to begin on March 5 at 8:00 am; not all company presentations may be webcasted. Webcast Link
News For ATRS;JAZZ;INFI;ABBV;ARAY;LXRX;IDRA;SSH;NKTR;ANTH;BDX;IMMU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 16, 2015
16:56 EDTSSHSunshine Heart says FDA requested minor protocol changes in COUNTER HF study
Subscribe for More Information
09:03 EDTNKTRBaxter submits application to Japan's MHLW for approval of BAX 855
Baxter International (BAX) announced that the company has submitted a new drug application to Japanís Ministry of Health, Labour and Welfare for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII treatment based on ADVATE for patients over 12 years of age with hemophilia A. The submission follows the filing to the United States Food and Drug Administration in late 2014 and is based on positive results from a prospective, global, Phase 3 study of 137 previously treated patients. The results, presented during the European Association for Haemophilia and Allied Disorders meeting in February 2015, demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding episodes and routine prophylaxis for patients who were 12 years or older. Baxter continues to advance a continuation study for patients who completed the pivotal trial and a Phase 3 study among previously treated patients under the age of 12 with severe hemophilia A. Once the pediatric study has been completed, the company expects to file for marketing authorization with the European Medicines Agency in 2016 and intends to seek post-approval label expansion in the U.S. for previously-untreated pediatric patients. BAX 855 is based on ADVATE, a full-length FVIII molecule with more than 12 years of real-world experience. Through a collaboration with Nektar Therapeutics (NKTR), BAX 855 leverages proprietary pegylation technology designed to extend the duration of activity of the protein in the body. This proprietary technology has been used for over 10 years in a number of approved medicines that treat chronic or serious conditions.
07:20 EDTATRSAntares Pharma announces settlement of patent infringement lawsuits
Subscribe for More Information
April 15, 2015
19:08 EDTABBVEnanta confirms AbbVie hepatitis C treatment granted priority review in Japan
Subscribe for More Information
19:03 EDTABBVAbbVie's chronic hepatitis C treatment granted priority review in Japan
Subscribe for More Information
12:01 EDTBDXBecton Dickinson price target raised to $167 from $160 at Piper Jaffray
Subscribe for More Information
09:08 EDTLXRXOn The Fly: Pre-market Movers
Subscribe for More Information
07:03 EDTLXRXLexicon and Bristol-Myers select development candidate for neuropathic pain
Subscribe for More Information
April 14, 2015
08:05 EDTINFIInfinity Pharmaceuticals names Sujay Kango as Chief Commercial Officer
Subscribe for More Information
07:05 EDTIDRANeedham to hold a conference
Subscribe for More Information
April 13, 2015
14:07 EDTABBVEarnings Watch: Johnson & Johnson shares down slightly since last earnings
Subscribe for More Information
10:00 EDTABBVOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:34 EDTABBVAbbVie upgraded on Imbruvica outlook at BMO Capital
Subscribe for More Information
07:02 EDTABBVAbbVie upgraded to Outperform from Market Perform at BMO Capital
April 8, 2015
05:30 EDTABBVEnanta announces data on regimens containing protease inhibitors paritaprevir
Subscribe for More Information
April 7, 2015
11:10 EDTNKTRNektar management to meet with Jefferies
Subscribe for More Information
10:10 EDTJAZZJazz patent on Xyrem latest to be challenged by Kyle Bass
Subscribe for More Information
07:31 EDTABBVBiogen to present data on neurological disease therapies at AAN meeting
Subscribe for More Information
April 6, 2015
13:32 EDTBDXBecton Dickinson, Breakout Labs form strategic relationship
Breakout Labs, Peter Thielís philanthropic revolving fund for early-stage science and technology companies, and BD announced that they have established a strategic relationship to provide additional grant funding and professional expertise to qualifying Breakout Labs portfolio companies. Under the terms of the agreement, BD will periodically review Breakout Labsí portfolio for companies developing cutting-edge technologies that are relevant to the strategic interests of BDís Medical and Life Sciences business segments. Breakout Labs companies selected to participate will be given an unrestricted grant of up to $25,000 from BD, and assigned a business mentor responsible for providing guidance and connections to subject matter experts throughout the company.
08:32 EDTIMMUImmunomedics to provide update on sacituzumab govitecan at AACR meeting
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use